Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $101 from $71 and keeps an Overweight rating on the shares. After the company reported first half results and attended the firm’s Global Healthcare Conference, the analyst sees higher odds of success for the Crohn’s indication for obefazimod following discussions with management.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax SA Reports Financial Results and Strategic Advances
- Promising Outlook for Abivax SA: Buy Rating Supported by Strong Clinical Results and Financial Position
- Abivax Reports Increased Losses but Secures Major Funding in H1 2025
- Abivax SA Sponsored ADR (ABVX) Q2 Earnings Cheat Sheet
- Abivax price target raised to $112 from $70 at Piper Sandler